SIU 2018: Technique for MR/US Fusion Prostate Biopsy
Seoul, South-Korea (UroToday.com) Ardeshir Rastinehad, MD finished off the Master Class by providing a brief overview to the technique for fusion biopsy – he provided some data, but passed along some important take-home points in the process. I highlight these primarily, as his talk was short on details but rather focused on broader concepts!
SIU 2018: Oncology Updates -ERAS Protocol
Seoul, South-Korea (UroToday.com) Jay Shah, MD presented ERAS (enhanced recovery after surgery) protocols and highlighted the work that still needs to be done in this arena.
He provided a brief history of ERAS and highlighted some basics of the ERAS protocols.
- Henrik Kehlet, MD PhD – General surgeon who started to look at things outside of surgical technique that could “fast track surgery”. Should receive credit for really starting this process
- Within urology, Raj Pruthi (UNC, USA) and Sia Daneshmand (USC, USA) helped pioneer this concept, both with cystectomy
SIU 2018: Urologists vs. Urinary Bugs: Time for a Truce?
Seoul, South-Korea (UroToday.com) J. Curtis Nickel, MD gave a talk on the history and future of infections in urology. When looking at the history of infections and the treatment of urinary tract infections in the 1800s, bacteria was then discovered as the cause of inflammation. Dr. Nickel presented a relevant anonymous quote, stating that “In the 19th century men lost their fear of God and acquired a fear of microbes”. Various strange treatments with questionable benefit were offered to patients with urinary tract infections. This included Hexylresorcinol (caprokol), lead, strychnine, and others.
SIU 2018: Management of Recurrent Non-Muscle Invasive Bladder Cancer
Seoul, South-Korea (UroToday.com) Maurizio Brausi, MD gave a detailed overview of the management of recurrent non-muscle invasive bladder cancer (NMIBC). Transurethral resection of bladder tumor (TURBT) with white light is the gold standard treatment for the diagnosis and treatment of NMIBC. However, the TURBT mush is adequate, with all visible tumors resected, with muscle present in the specimen, with no bladder perforation and no bleeding encountered.
SIU 2018: Cell Therapy and Constructs – Why is it Not Yet in Clinical Use?
Seoul, South-Korea (UroToday.com) James J. Yoo, MD gave an overview on the growing field of cell therapy and constructs and provided some of the experience from his own center, at the Wake Forest Institute for Regenerative Medicine, at the Wake Forest school of medicine, in North Carolina.
SIU 2018: Early Cystectomy for High-Risk NMIBC: Is it Appropriate?
Seoul, South-Korea (UroToday.com) Seth Lerner, MD gave the last session of the masterclass on managing recurrent non-muscle invasive bladder cancer (NMIBC), focusing on early cystectomy for high-risk NMIBC. When comparing T1 high grade (HG) with T1 HG with carcinoma in situ (CIS), the survival for patients presenting with T1 HG and CIS is considerably worse. In a similar manner to the European Association of Urology (EAU) guidelines, the American Urologic Association (AUA) guidelines also risk stratify NMIBC patients to low, intermediate, and high risk, as seen in Table 1.
SIU 2018: The Use of Ultrasound and mpMRI in the Diagnosis of Prostate Cancer
Seoul, South-Korea (UroToday.com) Peter Hammerer, MD, presented the utilization of ultrasound and mpMRI in the diagnosis of prostate cancer. He believes it is time we embrace mpMRI before the first biopsy. Currently, mpMRI is considered in several scenarios. These include: following a negative transrectal ultrasound (TRUS) guided biopsy and rising PSA, in cases of rising PSA before any biopsy, follow-up in active surveillance, cancer localization before focal treatment, and local staging for biopsy-proven prostate cancer.